Development of treatment strategies for advanced neuroblastoma

International Journal of Clinical Oncology

Volumn 17, Issue 3, 2012, Pages 196-203

  Hara, Junichi ^a  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

Author keywords

High risk; Neuroblastoma; Review; Treatment

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; ALISERTIB; ANAPLASTIC LYMPHOMA KINASE; AURORA KINASE INHIBITOR; BUSULFAN; CARBOPLATIN; CH 14.18; CHIMERIC ANTIBODY; CISPLATIN; CRIZOTINIB; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; FENRETINIDE; GANGLIOSIDE GD2 ANTIBODY; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2; IRINOTECAN; ISOTRETINOIN; MELPHALAN; MONOCLONAL ANTIBODY; RETINOID DERIVATIVE; SORAFENIB; TAE 684; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VOLASERTIB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CHEMOSENSITIVITY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; EVENT FREE SURVIVAL; GENE MUTATION; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE THERAPY; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROBLASTOMA; NEUROPATHIC PAIN; NONHUMAN; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; TUMOR SCINTISCANNING;

ANTINEOPLASTIC AGENTS; CHILD; CONSOLIDATION CHEMOTHERAPY; HUMANS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; NEUROBLASTOMA;

EID: 84862873055     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0417-5     Document Type: Review

References (73)

1. London WB, Castleberry RP, Matthay KK et al (2005) Evidence for age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465
2. Cohn SL, Pearson AD, London WB et al (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 27:289-297
3. Yamamoto K, Harada R, Kikuchi A et al (1998) Spontaneous regression of localized neuroblastoma detected by mass screening. J Clin Oncol 16:1265-1269
4. Carlsen NL (1990) How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 61:441-446
5. Cheung NV, Heller G (1991) Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol 9:1050-1058
6. Halperin EC, Cox EB (1986) Radiation therapy in the management of neuroblastoma: the Duke University Medical Center experience 1967-1984. Int J Radiat Oncol Biol Phys 12:1829-1837
7. Russo C, Cohn SL, Petruzzi MJ et al (1997) Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: a report from the Pediatric Oncology Group. Med Pediatr Oncol 28:284-288
8. Matthay KK, Villablanca JG, Seeger RC et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med 341:1165-1173
9. Sawaguchi S, Kaneko M, Uchino J et al (1990) Treatment of advanced neuroblastoma with emphasis on intensive induction chemotherapy. A report from the Study Group of Japan. Cancer 66:1879-1887
10. Pearson AD, Pinkerton CR, Lewis IJ et al (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 3:247-256
11. Vassal G, Doz F, Frappaz D et al (2003) A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 21:3844-3852
12. Bomgaars LR, Bernstein M, Krailo M et al (2007) Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 25:4622-4627
13. Vassal G, Giammarile F, Brooks M et al (2008) A phase II study of irinotecan in children with relapsed or refractory neuroblas-toma: a European cooperation of the Société Française d'On-cologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer 44:2453-2460
14. Saylors RL 3rd, Stine KC, Sullivan J et al (2001) Cyclophos-phamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 19:3463-3469
15. Kretschmar CS, Kletzel M, Murray K et al (2004) Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study. J Clin Oncol 22:4119-4126
16. Park JR, Scott JR, Stewart CF et al (2011) Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. J Clin Oncol 29:4351-4357
17. London WB, Frantz CN, Campbell LA et al (2010) Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol 28:3808-3815
18. Berthold F, Boos J, Burdach S et al (2005) Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol 6:649-658
19. Ladenstein RL, Poetschger U, Luksch R et al (2011) Busulphan-melphalan as a myeloablative therapy (MAT) for high-risk neu-roblastoma: results from the HR-NBL1/SIOPEN trial. J Clin Oncol 29(Suppl; abstr 2)
20. Matthay KK, Reynolds CP, Seeger RC et al (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a Children's Oncology Group study. J Clin Oncol 27:1007-1013
21. Matthay KK, Tan JC, Villablanca JG et al (2006) Phase I dose escalation of iodine-131-metaiodobenzylguanidine with my-eloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study. J Clin Oncol 24:500-506
22. Monnereau-Laborde S, Munzer C, Valteau-Couanet D et al (2011) A dose-intensive approach (NB96) for induction therapy utilizing sequential high-dose chemotherapy and stem cell rescue in high-risk neuroblastoma in children over 1 year of age. Pediatr Blood Cancer 57:965-971
23. Pradhan KR, Johnson CS, Vik TA et al (2006) A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hemato-poietic support. Pediatr Blood Cancer 46:793-802
24. Qayed M, Chiang KY, Ricketts R et al (2012) Tandem stem cell rescue as consolidation therapy for high-risk neuroblastoma. Pediatr Blood Cancer 58:448-452
25. Kreissman SG, Villablanca JG, Seeger RC et al (2008) A randomized phase III trial of myeloablative autologous peripheral blood stem cell (PBSC) transplant (ASCT) for high-risk neuro-blastoma (HR-NB) employing immunomagnetic purged (P) versus unpurged (UP) PBSC: a Children's Oncology Group study. J Clin Oncol 26(Suppl; abstr 10011)
26. Sidell N (1982) Retinoic acid-induced growth inhibition and morphologic differentiation of human neuroblastoma cells in vitro. J Natl Cancer Inst 68:589-596
27. Reynolds CP, Matthay KK, Villablanca JG et al (2003) Retinoid therapy of high-risk neuroblastoma. Cancer Lett 197:185-192
28. Villablanca JG, London WB, Naranjo A et al (2011) Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fen-retinide) in pediatric patients with refractory or recurrent neuro-blastoma: a report from the Children's Oncology Group. Clin Cancer Res 17:6858-6866
29. Modak S, Cheung NK (2007) Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest 25:67-77
30. Frost JD, Hank JA, Reaman GH et al (1997) A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 80:317-333
31. Yu AL, Uttenreuther-Fischer MM, Huang CS et al (1998) Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol 16:2169-2180
32. Ozkaynak MF, Sondel PM, Krailo MD et al (2000) Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's Cancer Group Study. J Clin Oncol 18:4077-4085
33. Kushner BH, Kramer K, Cheung NK (2001) Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macro-phage colony-stimulating factor for neuroblastoma. J Clin Oncol 19:4189-4194
34. Osenga KL, Hank JA, Albertini MR et al (2006) A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res 12:1750-1759
35. Shusterman S, London WB, Gillies SD et al (2010) Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neu-roblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol 28:4969-4975
36. Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuro-blastoma. N Engl J Med 363:1324-1334
37. Kushner BH, Kramer K, Modak S et al (2011) Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. J Clin Oncol 29:1168-1174
38. Cheung NK, Kushner BH, Yeh SD et al (1998) 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: a phase II study. Int J Oncol 12:1299-1306
39. Mueller BM, Romerdahl CA, Gillies SD et al (1990) Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol 144:1382-1386
40. Simon T, Hero B, Faldum A et al (2004) Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol 22:3549-3557
41. Gilman AL, Ozkaynak MF, Matthay KK et al (2009) Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J Clin Oncol 27:85-91
42. Smith MA, Maris JM, Gorlick R et al (2011) Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer. doi:10.1002/pbc.23357
43. Lock RB, Carol H, Morton CL et al (2012) Initial testing of the CENP-E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatr Blood Cancer 58:916-923
44. Smith MA, Maris JM, Lock R et al (2011) Initial testing (stage 1) of the polyamine analog PG11047 by the pediatric preclinical testing program. Pediatr Blood Cancer 57:268-274
45. Kolb EA, Gorlick R, Houghton PJ et al (2008) Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pe-diatr Blood Cancer 50:1190-1197
46. Houghton PJ, Morton CL, Gorlick R et al (2010) Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the Pedi-atric Preclinical Testing Program. Pediatr Blood Cancer 54:921-926
47. Kolb EA, Gorlick R, Lock R et al (2011) Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 56:595-603
48. Maris JM, Morton CL, Gorlick R et al (2010) Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer 55:26-34
49. Maris JM, Courtright J, Houghton PJ et al (2008) Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer 51:42-48
50. Smith MA, Morton CL, Phelps DA et al (2008) Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alves-pimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer 51:34-41
51. Maris JM, Courtright J, Houghton PJ et al (2008) Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:581-587
52. Faisal A, Vaughan L, Bavetsias V et al (2011) The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Mol Cancer Ther 10:2115-2123
53. Kakodkar NC, Peddinti RR, Tian Y et al (2011) Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. Pediatr Blood Cancer. doi:10.1002/pbc.240047
54. Yang F, Jove V, Buettner R et al (2012) Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biol Ther [Epub ahead of print]
55. Grinshtein N, Datti A, Fujitani M et al (2011) Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 71:1385-1395
56. Barr FA, Silljé HH, Nigg EA (2004) Polo-like kinases and the orchestration of cell division. Nat Rev Mol Cell Biol 5:429-441
57. Downward J (2009) Finding the weakness in cancer. N Engl J Med 361:922-924
58. Luo J, Emanuele MJ, Li D et al (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137:835-848
59. Chen Y, Takita J, Choi YL et al (2008) Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455:971-974
60. George RE, Sanda T, Hanna M et al (2008) Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455:975-978
61. Bai RY, Dieter P, Peschel C et al (1998) Nucleophosmin-ana-plastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 18:6951-6961
62. Bai RY, Ouyang T, Miething C et al (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase/Akt anti-apoptotic signaling pathway. Blood 96:4319-4327
63. Slupianek A, Nieborowska-Skorska M, Hoser G et al (2001) Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 61:2194-2199
64. Amin HM, McDonnell TJ, Ma Y et al (2004) Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma. Oncogene 23:5426-5434
65. Duyster J, Bai RY, Morris SW (2001) Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 20:5623-5637
66. Shiota M, Fujimoto J, Semba T et al (1994) Hyperphosphoryla-tion of a novel 80 kDa protein-tyrosine kinase similar to Ltk in a human Ki-1 lymphoma cell line, AMS3. Oncogene 9:1567-1574
67. Iwahara T, Fujimoto J, Wen D et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14:439-449
68. Morris SW, Naeve C, Mathew P et al (1997) ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 14:2175-2188
69. PulfordK,LamantL,MorrisSWetal(1997)Detectionofanaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1. Blood 89:1394-1404
70. Lamant L, Pulford K, Bischof D et al (2000) Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol 156:1711-1721
71. Bresler SC, Wood C, Haglund EA et al (2011) Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med 3:108ra114
72. Heuckmann JM, Hölzel M, Sos ML et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17:7394-7401
73. Carpenter EL, Haglund EA, Mace EM et al (2012) Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma. Oncogene. doi:10.1038/onc.2011.647